Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketanserin, Olanzapine, and Lorazepam After LSD
NCT05964647Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketanserin, olanzapine and lorazepam in drug-induced psychosis (5 arms), sponsored by University Hospital Basel. Primary endpoints: Duration of subjective response at 18 months and Extent of subjective response at 18 months. Started Feb 2024; status: completed.
02
Drugs
ketanserinolanzapinelorazepam
03
Conditions
drug-induced psychosis
Beyond the preview
Go deeper on NCT05964647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05964647.